HIV/HBV合并感染患者基于替诺福韦的抗逆转录病毒治疗长达15年的持续性HBV复制与血清学应答:多中心前瞻性队列研究
该多中心前瞻性队列研究随访165例接受基于替诺福韦抗逆转录病毒治疗的HIV/HBV合并感染患者,中位治疗8.1年。92.1%患者实现HBV病毒学应答(HBV-DNA<60 IU/mL),持续病毒血症随时间减少;HBsAg血清清除仅见于实现病毒学应答者(1.0/100人年 vs 0/100人年,P=0.49)。
要点
- 长期替诺福韦治疗中92.1%的HIV/HBV合并感染者可实现HBV病毒学应答(<60 IU/mL)。
- HBV-DNA可检出率随治疗时间下降:5年15.1%,10年3.2%,15年3.2%。
- HBsAg血清清除仅见于实现HBV病毒学应答者,且HIV抑制更充分者更常见。
核心结论
- 长期基于替诺福韦的ART中,持续性HBV病毒血症存在但随时间减少,HBsAg血清清除仅见于实现完全HBV抑制及较高HIV抑制者。
研究设计与样本
- 多中心前瞻性队列研究,纳入165例接受基于替诺福韦ART的HIV/HBV合并感染患者,中位随访8.1年(IQR 4.0-13.2)。
主要发现
- 152例(92.1%)实现病毒学应答(HBV-DNA<60 IU/mL),13例(7.9%)从未实现。
- HBV-DNA≥60 IU/mL的比例在5年、10年、15年分别为15.1%(14/93)、3.2%(2/62)、3.2%(1/31)。
- 44/96例HBeAg阳性患者发生HBeAg血清清除(6.15/100人年),13/165例发生HBsAg血清清除(0.87/100人年)。
- 实现与未实现病毒学应答者的HBeAg血清清除率无差异(7.4 vs 3.7/100人年,P=0.33)。
- HBsAg血清清除仅见于实现病毒学应答者(1.0 vs 0/100人年,P=0.49),且病毒学应答者HIV-RNA不可测频率更高(P<0.001)。
关键数值与推荐
- 病毒学应答定义为HBV-DNA<60 IU/mL。
- HBeAg血清清除率6.15/100人年,HBsAg血清清除率0.87/100人年。
临床怎么用
- 对HIV/HBV合并感染者应长期监测HBV-DNA及HBeAg/HBsAg,实现HBV病毒学应答有助于HBsAg清除。
- 持续HBV病毒血症者需关注依从性及耐药,尽管随时间减少但仍需定期评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the extent of hepatitis B virus (HBV) suppression and its association with seroclearance of hepatitis 'e' antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HIV/HBV-coinfected patients undergoing long-term tenofovir-based antiretroviral therapy (ART). METHODS: We prospectively followed 165 HIV/HBV-coinfected patients undergoing tenofovir-based ART. Serum HBV-DNA viral loads and HBeAg and HBsAg status were obtained at tenofovir initiation and every 6-12 months. We calculated the proportion achieving virological response (VR, <60 IU/mL) during follow-up. We also calculated rates of HBeAg- and HBsAg-seroclearance, which were compared between those who achieved versus never achieved VR during follow-up using an Exact binomial test. RESULTS: During a median 8.1 years (IQR = 4.0-13.2) of tenofovir treatment, 152 (92.1%) patients were able to achieve VR and 13 (7.9%) never achieved VR (median HBV-DNA at the end of follow-up = 608 IU/mL, range = 67-52 400 000). The prevalence of individuals with detectable HBV-DNA (≥60 IU/mL) decreased during tenofovir treatment: 15.1% (n = 14/93) at 5 years, 3.2% (n = 2/62) at 10 years and, 3.2% (n = 1/31) at 15 years. 44/96 HBeAg-positive patients (6.15/100 person-years) had HBeAg-seroclearance and 13/165 patients overall (0.87/100 person-years) had HBsAg-seroclearance. No difference in HBeAg-seroclearance was observed between those who achieved versus never achieved VR (7.4 versus 3.7/100 person-years, P = 0.33), while HBsAg-seroclearance was only observed in those with VR (1.0 versus 0/100 person-years, P = 0.49; respectively). Individuals with VR also had a higher frequency of undetectable HIV-RNA during treatment (P < 0.001). CONCLUSIONS: During long-term tenofovir-based ART for HIV/HBV coinfection, persistent HBV viraemia is apparent, but becomes less frequent over time. HBsAg-seroclearance only occurred in those with full HBV and relatively high HIV suppression.
引用
- Dezanet LNC, Miailhes P, Lascoux-Combe C, et al. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. J Antimicrob Chemother. 2021. PMID: 34458919. doi:10.1093/jac/dkab294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。